荣昌生物(688331) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was RMB 330,434,802.62, representing a year-on-year increase of 96.41%[4] - The net profit attributable to shareholders was a loss of RMB 348,921,696.49, with a net profit excluding non-recurring items also showing a loss of RMB 345,576,207.04[4] - Total operating revenue for Q1 2024 reached RMB 330,434,802.62, a significant increase from RMB 168,238,991.99 in Q1 2023, representing a growth of 96.5%[18] - The net profit for Q1 2024 was a loss of RMB 348,921,696.49, compared to a loss of RMB 323,774,631.80 in Q1 2023, showing a decline of 7.8%[19] - Total comprehensive loss for Q1 2024 was RMB -372,204,285.59, compared to RMB -326,630,103.58 in Q1 2023, reflecting an increase in losses of 13.9%[19] Cash Flow and Liquidity - The net cash flow from operating activities was negative at RMB 426,289,929.83[4] - Cash flow from operating activities in Q1 2024 was negative at RMB -426,289,929.83, compared to RMB -349,845,397.38 in Q1 2023, indicating a worsening cash flow situation[21] - Cash and cash equivalents at the end of Q1 2024 stood at RMB 619,732,575.42, down from RMB 1,086,332,437.19 at the end of Q1 2023, a decrease of 42.9%[21] - The company reported cash and cash equivalents of CNY 622.79 million, down from CNY 743.39 million[16] - The company received cash inflows from operating activities totaling RMB 289,128,725.27 in Q1 2024, compared to RMB 224,413,979.30 in Q1 2023, an increase of 28.8%[21] - Investment activities resulted in a net cash outflow of RMB -81,362,490.71 in Q1 2024, compared to RMB -584,089,411.54 in Q1 2023, indicating an improvement in investment cash flow[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,478,656,892.82, a decrease of 0.90% from the end of the previous year[5] - As of March 31, 2024, total assets amounted to approximately CNY 5.48 billion, a decrease from CNY 5.53 billion as of December 31, 2023[16] - Current assets totaled CNY 2.20 billion, slightly down from CNY 2.23 billion in the previous period[16] - Total liabilities increased to CNY 2.40 billion from CNY 2.09 billion, indicating a rise in financial obligations[17] - The company's equity attributable to shareholders decreased to CNY 3.08 billion from CNY 3.44 billion[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,422[9] - The number of A-share shareholders totaled 5,397, while H-share shareholders numbered 25, totaling 5,422 shareholders[12] - The company has engaged in securities lending, with 1,425,000 shares lent out, representing 0.26% of total shares[13] Research and Development - R&D investment totaled RMB 331,178,800.01, which accounted for 100.23% of operating revenue, a decrease of 48.20 percentage points compared to the previous year[5][8] - Research and development expenses rose to RMB 331,178,800.01 in Q1 2024, compared to RMB 249,722,218.25 in Q1 2023, reflecting a growth of 32.5%[18] Inventory and Receivables - Inventory levels rose to CNY 751.47 million, compared to CNY 741.56 million previously[16] - Accounts receivable stood at CNY 296.38 million, showing a slight decrease from CNY 297.68 million[16] - The company has a short-term loan of CNY 574.00 million, significantly higher than CNY 284.28 million reported earlier[17]